REG - Avacta Group PLC - Management Team Appointments

AvactaAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250701:nRSA0880Pa&default-theme=true

RNS Number : 0880P  Avacta Group PLC  01 July 2025

 

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and
Yulii Bogatyrenko as Advisor in Business Development

LONDON and PHILADELPHIA - July 1, 2025 - Avacta Group plc (AIM: AVCT), a life
sciences company developing innovative, targeted oncology drugs, today
announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical
Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr.
Liebowitz will lead the Company's clinical strategy and execution as it
continues to advance its pipeline of targeted cancer therapies and Mr.
Bogatyrenko will add additional strength to the Group's business development
strategy.

Dr. Liebowitz is a seasoned hematologist-oncologist and drug development
leader with more than 30 years of experience across academia and industry and
has contributed to the successful filing of more than 25 Investigational New
Drug (IND) applications. He joins Avacta from Inovio Pharmaceuticals (Nasdaq:
INO), where he served as Senior Vice President of early-stage clinical
development, overseeing the clinical strategy for DNA-based vaccines and
immunotherapies. Prior to that, he held senior roles at Xencor, Vaxart, and
Amgen, with a consistent focus on oncology, immunotherapy, and translational
science. At Vaxart, Dr. Liebowitz led the acquisition and execution of a
significant BARDA contract as principal investigator, culminating in
successful completion of the award. Earlier in his career, he held key R&D
leadership roles at Amgen, where he directed oncology and vascular biology
drug discovery at the company's Washington research site.

Dr. Liebowitz began his academic career at the University of Chicago, where he
served as Assistant Professor of Medicine and Virology and Director of the
Bone Marrow Transplantation Program. He later became an associate investigator
at the University of Pennsylvania's Abramson Cancer Institute, where he led
immunotherapy and cellular therapy programs focused on cancer and chronic
viral diseases, and was a recipient of a Bill & Melinda Gates Foundation
grant. Dr. Liebowitz holds MD and PhD. degrees from the University of Chicago
and BS and MS degrees from Emory University.

Mr. Bogatyrenko is a Principal at Biopharma C&I, a biotechnology
consulting firm that works with private and public companies in business
development, corporate strategy, commercialization, launch readiness and
R&D strategy.  Previously, he held senior level positions in business
development and commercial strategy, including leading multiple global
commercial drug launches and numerous industry partnerships at Pfizer/Wyeth,
Bayer Healthcare and Teva Specialty Pharmaceuticals.

Christina Coughlin, MD, PhD, CEO of Avacta, commented:

"We are thrilled to welcome David and Yulii at this pivotal time for Avacta.
David's deep expertise in oncology, coupled with a successful track record of
advancing innovative therapies into the clinic, will be instrumental as we
continue to execute on our clinical development strategy and progress our
pre|CISION™ platform and pipeline of targeted cancer therapies. Yulii's deep
experience across commercial strategy, global drug launches, and industry
partnerships at leading pharma organizations will be invaluable as we advance
our pipeline and corporate growth strategy."

"We look forward to benefiting from their insights and strategic perspective
as we remain focused on driving value for both patients and shareholders."

-Ends -

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                           https://avacta.com/ (https://avacta.com/)

 Michael Vinegrad,

 Group Communications Director

 Peel Hunt (Nomad and Joint Broker)                          www.peelhunt.com (http://www.peelhunt.com)

 James Steel / Chris Golden

 Panmure Liberum (Joint Broker)                              www.panmureliberum.com

 Emma Earl / Will Goode / Mark Rogers

 Zeus (Joint Broker)                                        www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry

 Dominic King

 ICR Healthcare

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert   avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Investor Contact                                           renee@thrustsc.com (mailto:renee@thrustsc.com)

 Renee Leck

 THRUST Strategic Communications

 Media Contact                                              Carly@carlyscadutoconsulting.com (mailto:Carly@carlyscadutoconsulting.com)

 Carly Scaduto

 Carly Scaduto Consulting

 

 

About Avacta - www.avacta.com (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary warhead delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent warheads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFVIRAIIVIE